8results about "Microcarriers" patented technology

A cell culture microcarrier bead is proposed. The microcarrier bead comprises a bead body having its surface flecked with plasmonic nanoparticles. In a second aspect, the invention relates to a cell culture reactor, containing a cell culture medium and the proposed microcarrier beads. A third aspect of the invention concerns a method for observing living cells on such microcarrier beads. Yet a further aspect of the invention relates to a method for packing nanoparticles on a carrier body.

The present invention relates to a method for the preparation of an assembly of cells and microrobots comprising (a) preparing a suspension of cells and microrobots, wherein the microrobots comprises an alginate, collagen, fibrin, hyaluronic acid / collagen, polyacrylamide, or polyethylene glycol hydrogel capsule, wherein the alginate is conjugated to cell adhesive peptides, and (b) incubating the suspension of (a) to allow the microrobots to form an assembly with the cells via the binding of the cell adhesive peptides to the cells, wherein step (b) and preferably steps (a) and (b) are performed in a conic microcentrifuge tube with a rounded bottom without corners and edges.

A substrate for culturing cells that comprises a modified prolamin having a net positive charge is provided. The modified prolamin may be a prolamin that has been modified through amidation or esterification, such as the addition of a methyl-ester group or an ethanolamine group. The modified prolamin is animal-free may be food-grade and / or may be free of cross-linkers. The modified prolamin may be in a coating that can be applied to a surface for culturing adherent cells, such as a microcarrier (e.g., beads) or well plates. Substrates coated with the modified prolamin are able to support cell expansion and can be used for food-grade applications such as cultured meat.

The present invention relates to a method for producing an in vitro model of a human neurological disease. Furthermore, the invention relates to the in vitro model produced according to the method disclosed herein. The invention also relates to the use of the in vitro model in drug testing. In addition, the invention relates to methods for testing the efficacy of drugs in preventing, delaying, and alleviating a human neurological disease.

Described herein are methods, compositions, and kits for the directed differentiation of human pluripotent stem cells, neuro-mesodermal progenitors, and neural stem cells into bioengineered oval neuroepithelial tissues and bioengineered neuroepithelial tubes that contain single rosettes of polarized neuroepithelial cells and have a microscale cellular organization similar to that of the developing human neural tube in vivo.

The present invention relates to a liquid, positively charged, responsive self- assembling peptide, a liquid scaffold material formed from the self-assembling peptide, and applications of the liquid scaffold material.

The present application relates to a kind of polymer composite microcarrier and its preparation method.It includes: microcarrier body, the microcarrier body includes synthetic polymer, the microcarrier body is hollow structure, the axial length of the microcarrier body is greater than the radial length of the microcarrier body;Functional area, the functional area is microporous structure, the functional area is formed on the microcarrier body, and the functional area includes natural macromolecule, or, the functional area includes natural macromolecule and inorganic salt.The polymer composite microcarrier of the present application can make cell adhere to the outer surface of hollow microcarrier, and the internal hollow structure can facilitate the flow of liquid, provide uniform, good microenvironment for large-scale expansion of cell, it is advantageous to improve the number of cell expansion.

The present invention relates to methods for obtaining an expanded population of skeletal muscle derived cells (SMDC). The present invention also refers to an expanded population of SMDCs obtained by the method according to the present invention and to an expanded population of SMDCs. Further, the present invention refers to an expanded population of SMDCs for use in a method for treatment of the human or animal body by surgery or therapy or for use as a pharmaceutical composition. In addition, the present invention refers to an expanded population of SMDCs for use in a method of preventing and / or treating neuromyopathies, myopathies and / or muscle dysfunctions such as a urinary and / or an anal incontinence.